ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Now Rated “Hold” by Sell-Side Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $99.60.

A number of equities research analysts recently commented on ANIP shares. Guggenheim lowered their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Oppenheimer assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 target price for the company. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Finally, Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $71.00, for a total value of $383,400.00. Following the completion of the transaction, the chief executive officer owned 339,089 shares in the company, valued at $24,075,319. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeanne Thoma sold 1,000 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the sale, the director owned 26,762 shares in the company, valued at $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 24,512 shares of company stock valued at $1,820,165. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $28,000. Versant Capital Management Inc grew its position in ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 217 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $76,000. State of Wyoming bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth $86,000. Finally, GAMMA Investing LLC lifted its holdings in ANI Pharmaceuticals by 13.4% in the third quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 211 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Down 0.4%

ANIP opened at $73.59 on Thursday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average price of $74.28 and a two-hundred day moving average price of $78.06. The company has a market cap of $1.69 billion, a P/E ratio of 15.86, a price-to-earnings-growth ratio of 2.38 and a beta of 0.50. ANI Pharmaceuticals has a 1-year low of $69.58 and a 1-year high of $97.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the company earned $1.80 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals will post 7.76 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.